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‘‘Correa” cascade has high level of induction in transforming into
non invase gastric cancer.
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Epidemiology of malignant neoplasms of the oral cavity and pharynx
in the territory of the Chelyabinsk region




The Chelyabinsk region is a classic example of the
technologically-saturated region. The index of pollution of
atmospheric air is estimated as high. The Chelyabinsk region is
among the areas of increased cancer risk. The incidence of head
and neck cancer is steadily increasing, accounting for 20–25% of
all cancer cases in Russia. Oropharyngeal cancer makes up 5.1%
of all cancers.
Materials and methods: The object of the study was the
population of the Chelyabinsk region. The analysis was
conducted according to the materials of the annual reports of
the statistics department of the Chelyabinsk district oncology
dispensary.
Results: Out of the total cancer cases for the population of Che-
lyabinsk region in 2014, oro-pharyngeal cancer comprised 2.06%,
including cancers of the lip (0.35%), tongue (0.47%), major salivary
glands (0.22%), other unspecified parts of the mouth (0.52%),
oropharynx (0.33%), nasopharynx (0.1%) and hypopharynx
(0.07%). From 2008 to 2014, the incidence of oral and pharyngeal
cancer among adult population of Chelyabinsk city and
Chelyabinsk region showed an 8.8% increase. In the period from
2011 to 2014, the incidence of oral and pharyngeal cancer tended
to increase, the overall rise being 71.8%. It should be noted that
the oral and pharyngeal cancer incidence was 3 times higher in
males than in females in 2013 and 2 times higher in 2014.
One of the main indicators that determine the prognosis for the
development of cancer, is the extent of tumor at time of
diagnosis.
Out of the total cancer cases for the population of Chelyabinsk
region in 2014, cancer of the oral cavity comprised 1.33%, pharyn-
geal cancer 0.6%, lip cancer 0.13%, ranking the 17th, 19th and 24th
place respectively among the causes of death from all cancers.
Analyzing the dynamics of mortality from cancer of the oral cav-
ity and pharynx during the study period, it was revealed that the
mortality rate increased by 0.7%.
Conclusion: Head and neck tumors are a rare group of clini-
cally and biologically diverse neoplastic diseases. Among the res-
idents of the Chelyabinsk region, men are 2–3 times more
susceptible to cancer of the oral cavity and pharynx than women.
High mortality rate is due to late referral of patients to specialized
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Background: To evaluate the clinical symptoms in pancreatic
cancer patients (PCa) and compare some biochemical blood
serum parameters in patients with different pathology of the
pancreas (PCa, acute (OP) and chronic pancreatitis (CP)).
Materials and methods: During a one-time clinical research on
the type of ‘‘series of cases” 130 patients were examined
(42 patients with OP, 81 – CP and 7 patients with PCa). The diagno-
sis of PCa, OP, CP was verified by clinical and instrumental
methods. Glucose, cholesterol, triglyceride and bilirubin serum
levels were determined by ELISA.
Results: The mean age of patients with PCa was 63.6
± 4.9 years, morbidity duration of PCa – 3.5 ± 1.1 months. Among
patients with PCa, 83.3% of people – smoked, 16.7% – smoked
every day. Half of the respondents PCa patients noted that over
the last year they did not drink alcohol; 16.7% of people – drank
alcohol several times a year, and 33.3% of patients consumed
alcohol 1–2 times a month. BMI of PCa patients was equal to
26.3 ± 3.5 kg/m2, in OP patients – 23.8 ± 1.0 kg/m2, in CP patients
– 26.3 ± 0.6 kg/m2, p > 0.05. In this case, 85.7% of PCa patients
noted a significant decrease in body weight (11.7 ± 6.0 kg) for
3–4 months after the onset of symptoms. There was no pain in
42.8% of PCa patients, and frequent pain noted only in 28.6% of
persons. Among CP patients, frequent and persistent pain noted
in 65.5% of patients and among OP patients in 48.6% of cases.
All PCa patients experienced pain in the right upper quadrant.
Pain was of low intensity in 75% of cases and moderate in 25%
of cases. Elimination of pain was observed in half of the PCa
patients, and 1/4 of patients continued to experience pain. Epi-
sodes of nausea and vomiting noted in 25% of PCa patients.
Bloated feeling in the stomach and overflow were noted in
42.8% of the all surveyed PCa persons. The level of glucose in
PCa patients exceeded the normal limits and was significantly
higher compared to that in OP and CP patients (8.5 ± 1.4 mmol/L,
5.4 ± 0.3 and 5.1 ± 0.1 mmol/L, respectively, p < 0.05). Hyperbiliru-
binemia was detected in PCa patients – 89.9 ± 27.5 lmol/L; in OP
and CP patients bilirubin levels were 32.2 ± 11.0 and 13.4
± 1.8 lmol/L, respectively, which were significantly lower than
those in patients with PCa, p < 0.05. Triglyceride levels did not
differ in patients with different pancreas diseases (PCa – 1.7 ± 0.3,
CP – 1.86 ± 0.1 and OP –1.88 ± 0.11 mmol/L, p > 0.05). However,
the total cholesterol in CP patients was significantly higher
than that in PCa and OP patients (5.8 ± 0.1, 5.0 ± 0.6 and
4.1 ± 0.2 mmol/L, p < 0.05). In PCa patients, the elevated levels of
some markers of cholestasis and hepatocyte injury were
also found: ALP – 185.0 ± 12.7 IU/L, ALT – 108.4 ± 33.5 IU/L,
AST – 85.3 ± 31.5 IU/L, amylase – 44.9 ± 14.9 IU/L, fibrinogen –
2696.6 ± 398.6 g/L.
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Conclusion: The combination of nonspecific clinical signs
(pain, dyspepsia) with biochemical markers of biliary pathology
and endocrine pancreatic insufficiency – of PCa patients demon-
strates the obligatoriness of differential diagnostic pancreatic and
biliary pathology in their earlier stages.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.027
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Acute myelomonocytic leukemia (FAB M4) is one of the most
common forms of acute myeloid leukemia (AML). This AML form
is characterized by rapid accumulation transformed myeloblasts
and monoblasts in bone marrow, with the rapid suppression of
normal hematopoiesis. Bone marrow microenvironment is one
of the main factors determining drug resistance of leukemic cells.
It is known that the adhesion of leukemic cells to mesenchymal
stem cell and bone marrow extracellular matrix (laminin,
collagen) enhances their drug resistance. However, it remains
unknown whether the emergence of drug resistance when
cell–cell contacts are formed only between leukemia cells,
without the involvement of bone marrow stromal elements. We
studied the role of cell aggregation in drug resistance of leukemic
cells. We used the bone marrow mononuclear cells (BMMC)
isolated from the patients with acute myelomonocytic leukemia.
For the formation of multicellular aggregates, BMMC were
cultivated in 96-well plates coated with 1.5% agarose. We showed
that resistance of BMMC to bortezomib, doxorubicin and
fludarabine in multicellular aggregates was increased. In three-
dimensional multicellular aggregates of BMMC index IC50 for
bortezomib, doxorubicin and fludarabine was 7 ± 1 ng/ml,
1 ± 0.4 mkM and 0.8 ± 0.05 mkM, respectively. In control condi-
tion, index IC50 bortezomib, doxorubicin and fludarabine was
significantly lower, 2 ± 0.5 ng/ml, 0.3 ± 0.05 mkM and 0.07 ±
0.001 mkM, respectively. In multicellular aggregates of BMMC
number of mitotic cells and expression of Ki-67 protein were
not significantly different from the control. It has also been
shown that cells in multicellular aggregates increased expression
antiapoptotic protein Bcl-2. Suppression of BMMC aggregation by
culturing the cells in medium containing 0.9% methylcellulose
resulted in decreased IC50 index for bortezomib, doxorubicin
and fludarabine, 2 ± 0.7 ng/ml, 0.12 ± 0.004 mkM and 0.04
± 0.005 mkM, respectively. Expression of the Bcl-2 protein was
also decreased. This work demonstrates the involvement of cell
aggregation in the formation of drug resistance phenotype in
leukemic cells.
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Blood-based biomarkers for lung cancer
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Blood-derived biomarkers, such as circulating tumour cells
(CTCs) and circulating tumour DNA (ctDNA), are a valuable source
of molecular genetic data for tumours they spring from. In trans-
lational cancer research, the ‘‘liquid biopsy” concept has been put
forward to denote the detection and molecular characterization
of these biomarkers.
The idea of liquid biopsy is based on a hypothesis that profiles
of somatic mutations in CTCs and ctDNA are identical to those in
the original tumour. Therefore, the mutation status of the source
tumour can be revealed through the molecular analysis of the
CTCs and ctDNA obtained from the blood. The major advantages
of liquid biopsy are an essentially decreased invasiveness (no
need for tissue biopsy, surgery or bronchoscopy) and an ability
to carry out the analysis at patient’s follow up (e.g. to monitor
for residual disease).
However, both the CTCs and ctDNA are not abundant in the
bloodstream and their capture is technically challenging. Also,
due to tumour heterogeneity, the CTCs may not fully represent
the entire tumour, while ctDNA is naturally fragmented and
degraded, so its utility for genetic analysis may be limited. Finally,
the DNA extracted from CTCs and, especially, ctDNA are ‘‘con-
taminated” by DNA from non-tumour cells from the bloodstream
raising a challenge of detecting mutant DNA among significantly
prevailing wild-type DNA.
Some of these issues can be overcome by using such advanced
techniques as BEAMing, digital PCR or ultra-deep sequencing, but
their use in standard clinical settings is limited by the need for
special equipment and associated costs. Inexpensive and less
sophisticated, but still highly sensitive and specific, approaches,
such as COLD-PCR or wild-type blocking PCR, are also available
to detect ‘‘druggable” mutations in CTCs and ctDNA.
Application of these approaches of liquid biopsy in clinical




Endogenous inhibitors of cysteine proteases and preform of cathepsin
B in cancer of reproductive system
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